NCT02877706 French Registry of Adult Patients With Immune Thrombocytopenia and Autoimmune Hemolytic Anemia
| NCT ID | NCT02877706 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Toulouse |
| Condition | Immune Thrombocytopenia |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,500 participants |
| Start Date | 2013-06 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,500 participants in total. It began in 2013-06 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
CARMEN is a national, real-world clinical registry of all adult patients with incident diagnosis of Immune thrombocytopenia (ITP) or Autoimmune Hemolytic anemia (AIHA) patients in France. It is aimed at describing ITP and AIHA clinical features, assessing the real-world risk-benefit ratio of treatments and adherence to guidelines for ITP and AIHA management.
Eligibility Criteria
Inclusion Criteria: * adult patients (18+ year-old) * newly diagnosed for ITP/AIHA or initiation of FOSFAMATINIB Exclusion criteria: \- opposition to data collection
Contact & Investigator
Moulis Guillaume, MD PhD
✉ moulis.g@chu-toulouse.frMoulis Guillaume, MD PhD
PRINCIPAL INVESTIGATOR
University Hopsital Toulouse
Frequently Asked Questions
Who can join the NCT02877706 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Immune Thrombocytopenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02877706 currently recruiting?
Yes, NCT02877706 is actively recruiting participants. Contact the research team at moulis.g@chu-toulouse.fr for enrollment information.
Where is the NCT02877706 trial being conducted?
This trial is being conducted at Toulouse, France.
Who is sponsoring the NCT02877706 clinical trial?
NCT02877706 is sponsored by University Hospital, Toulouse. The principal investigator is Moulis Guillaume, MD PhD at University Hopsital Toulouse. The trial plans to enroll 1,500 participants.